A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)

Zheng, Yan; Liu, Xianben; Sun, Haibo; Xu, Jinliang; Shen, Shuxin; Ba, Yue; Yan, Ming; Qin, Zimin; Liu, Baoxing; Wang, Zongfei; Liu, Shilei; Zhang, Rui-Xiang; Chen, Pei-Nan; Liang, Guanghui; Yuan, Dandan; Li, Zhen-xuan; Liu, Qi; Wang, Haoran; Li, Haomiao; Lv, Hongwei; Ma, Xiaochao; Zhu, Jianping; Yu, Yonghao; Xing, Wei

doi:10.21037/atm-20-5404

Cited by 35 publications

(30 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toripalimab, a new type of recombinant humanized IgG4 monoclonal antibody against PD-1, has shown promising efficacy and safety in a series of clinical studies. 7 , 8 , 9 , 10 However, there is little evidence as to whether a regimen that combines toripalimab with GS would lead to comparable or better outcomes when administered in patients with advanced BTCs.…”

Section: Introductionmentioning

confidence: 99%

Toripalimab in advanced biliary tract cancer

Liu¹

2022

The Innovation

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Toripalimab in advanced biliary tract cancer

Liu¹

2022

The Innovation

View full text Add to dashboard Cite

“…Recently, pembrolizumab plus chemotherapy has been recommended as first-line treatment for advanced EC ( 10 ). Considering the promising results in advanced EC, it is reasonable to explore the efficacy and safety of neoadjuvant immunotherapy combined chemotherapy (nICT) ( 11 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study

et al. 2021

View full text Add to dashboard Cite

BackgroundCombination of neoadjuvant immunotherapy and chemotherapy (nICT) is a novel treatment for locally esophageal cancer squamous cell carcinoma (ESCC). This study aimed to evaluate the potential effect of nICT on surgery safety by comparing short-term outcomes between the surgery alone group and the nICT followed by surgery group.MethodsA retrospective analysis was performed to identify patients (from January 2017 to July 2021) who underwent surgery for ESCC with or without nICT. A propensity score matching (PSM) comparison (1:1) was conducted to reduce selection biases and balance the demographic and oncologic characteristics between groups.ResultsAfter PSM, the nICT group (n = 38) was comparable to the surgery alone group (n = 38) in the following characteristics: age, sex, BMI, ASA status, smoking, tumor location, lymph node resection, clinical stage, anastomotic location, surgical approach, and surgical approach. The operation time and incidence of postoperative pneumonia in the nICT group were higher than those in the control group (p < 0.05). However, other complications and major complications were comparable between the two groups. There was no significant difference between the two groups in intraoperative blood loss, ICU stay time, postoperative hospital stay, and hospitalization cost. The 30-day mortality, 30-day readmission, and ICU readmission rates were also similar in the nICT and control groups. In the nICT group, the pathological complete response rate in primary tumor was 18.4%, and the major pathological response rate in tumor was 42.1%.ConclusionsBased on our preliminary experience, nICT followed by surgery is safe and effective with acceptable increased operation risk, manageable postoperative complications, and promising pathological response. Further multicenter prospective trials are needed to validate our results.

show abstract

“…Here, we explored the influence of the COVID-19 pandemic and lockdown policies on cancer patients in Henan by interrupted time series (ITS) analysis using autoregressive integrated moving average (ARIMA) models, which take the autocorrelation, underlying long-term trends, and seasonality into consideration. As the only tertiary cancer hospital in Henan, Henan Cancer Hospital has a bed capacity of over 3,000, about 660,000 outpatient visits, and 180,000 hospitalizations annually ( 19 ). Henan Cancer Hospital is an oncology specialist hospital and, therefore, does not admit patients with COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Delayed Diagnosis and Treatment of Cancer Patients During the COVID-19 Pandemic in Henan, China: An Interrupted Time Series Analysis

Liu

Piao

Zhang

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

ObjectiveTo investigate the possible impact of lockdown policies on the diagnosis and treatment of cancer patients in Henan, China.Design, Setting, and ParticipantsWe collected data from the Henan Cancer Hospital, affiliated with Zhengzhou University. The monthly numbers of inpatient admissions from January 2014 to December 2019 were used to forecast the number of inpatient admissions in 2020, which was then compared to the actual number of patients admitted during the pandemic to evaluate how the actual number diverges from this forecast. We conducted an interrupted time series analysis using the autoregressive integrated moving average (ARIMA) model.Main Outcomes and MeasuresFor specific diagnoses, treatment modalities, and age groups, we compared the changes in monthly admissions after the pandemic with the forecasted changes from the model.ResultsThe observed overall monthly number of inpatient admissions decreased by 20.2% [95% confidence interval (CI), 11.7–27.2%], 78.9% (95% CI, 77.3–80.4%), and 40.9% (95% CI, 35.6–45.5%) in January, February, and March 2020, respectively, as compared with those predicted using the ARIMA model. After the lockdown, visits for all treatment modalities decreased sharply. However, apparent compensation and recovery of the backlog appeared in later surgeries. As a result, the number of patients who underwent surgery in 2020 (30,478) was close to the number forecasted by the ARIMA model (30,185). In the same period, patients who received other treatments or underwent examinations were 106,074 and 36,968, respectively; the respective numbers that were forecasted by ARIMA were 127,775 and 60,025, respectively. These findings depict a decrease of 16.9 and 38.4% in patients who received other treatments or underwent examinations only, respectively. Regarding diagnosis, the reported incidence of various cancers decreased dramatically in February, with varying extent and speed of recovery.Conclusion and RelevanceThe COVID-19 pandemic has significantly delayed the diagnosis and treatment of cancer in Henan, China. Long-term research should be conducted to assess the future effects of lockdown policies.

show abstract

A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)

Cited by 35 publications

References 33 publications

Toripalimab in advanced biliary tract cancer

Toripalimab in advanced biliary tract cancer

Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study

Delayed Diagnosis and Treatment of Cancer Patients During the COVID-19 Pandemic in Henan, China: An Interrupted Time Series Analysis

Contact Info

Product

Resources

About